Cargando…

Time-dependent effect of antipsychotic discontinuation and dose reduction on social functioning and subjective quality of life–a multilevel meta-analysis

BACKGROUND: Meta-analyses indicate superiority of antipsychotic maintenance treatment over discontinuation within up to 24 months after treatment initiation for patients with schizophrenia-spectrum disorders. In terms of functional recovery, long-term trials show improved functioning after discontin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schlier, Björn, Buck, Laura, Müller, Rebecca, Lincoln, Tania M., Bott, Antonia, Pillny, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663674/ https://www.ncbi.nlm.nih.gov/pubmed/38021372 http://dx.doi.org/10.1016/j.eclinm.2023.102291

Ejemplares similares

Predictors of successful discontinuation of antipsychotics and antidepressants
por: Lincoln, Tania M., et al.
Publicado: (2023)

RELATE—a randomised controlled feasibility trial of a Relating Therapy module for distressing auditory verbal hallucinations: a study protocol
por: Lincoln, Tania M, et al.
Publicado: (2021)

Dose Reduction/Discontinuation of Antipsychotic Drugs in Psychosis; Effect on Cognition and Functional Outcomes
por: Omachi, Yoshie, et al.
Publicado: (2018)

Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation and Reduction)
por: Moncrieff, Joanna, et al.
Publicado: (2019)

Correction: Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation and Reduction)
Publicado: (2020)

Mental health professionals’ views and experiences of antipsychotic reduction and discontinuation
por: Cooper, Ruth E., et al.
Publicado: (2019)

Expanding the positivity offset theory of anhedonia to the psychosis continuum
por: Riehle, Marcel, et al.
Publicado: (2022)

Are effort‐based decision‐making tasks worth the effort?—A study on the associations between effort‐based decision‐making tasks and self‐report measures
por: Renz, Katharina E., et al.
Publicado: (2022)

Experiences of reduction and discontinuation of antipsychotics: a qualitative investigation within the RADAR trial
por: Morant, Nicola, et al.
Publicado: (2023)

S227. A PROPOSED ALTERNATIVE BETWEEN DISCONTINUATION AND MAINTENANCE OF ANTIPSYCHOTICS: A GUIDED DOSE REDUCTION TRIAL FOR PATIENTS WITH REMITTED PSYCHOSIS
por: Liu, Chen-Chung
Publicado: (2018)

Risk factors for psychotic relapse in chronic schizophrenia after dose-reduction or discontinuation of antipsychotics. A systematic review and meta-analysis
por: Bogers, J., et al.
Publicado: (2021)

T246. RISK FACTORS FOR PSYCHOTIC RELAPSE IN CHRONIC SCHIZOPHRENIA AFTER DOSE-REDUCTION OR DISCONTINUATION OF ANTIPSYCHOTICS: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Bogers, Jan, et al.
Publicado: (2020)

Efficacy of Psychological Treatments for Patients With Schizophrenia and Relevant Negative Symptoms: A Meta-Analysis
por: Riehle, Marcel, et al.
Publicado: (2020)

Antipsychotic dose reduction compared to dose continuation for people with schizophrenia
por: Rodolico, Alessandro, et al.
Publicado: (2022)

“Goals in Focus”—a targeted CBT approach for motivational negative symptoms of psychosis: study protocol for a randomized-controlled feasibility trial
por: Schormann, Alisa L. A., et al.
Publicado: (2023)

Off the RADAR; questions regarding the trial protocol of a randomised controlled trial of antipsychotic reduction and discontinuation
por: Jauhar, Sameer, et al.
Publicado: (2023)

In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine
por: Luykx, Jurjen J., et al.
Publicado: (2020)

Discontinuation and dose reduction of rituximab in relapsing–remitting multiple sclerosis
por: Boremalm, Malin, et al.
Publicado: (2021)

An analysis of views about supported reduction or discontinuation of antipsychotic treatment among people with schizophrenia and other psychotic disorders
por: Crellin, Nadia E., et al.
Publicado: (2022)

Persistence of Antipsychotic Use After Clozapine Discontinuation: A Real‐World Study Across Antipsychotics
por: Stam, Noraly, et al.
Publicado: (2020)

To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial
por: Begemann, Marieke J. H., et al.
Publicado: (2020)

S204. REDUCTION OF ANTIPSYCHOTIC DOSES AND POLYPHARMACY: TWO COCHRANE REVIEWS
por: Leucht, Stefan, et al.
Publicado: (2020)

The comparison of glucose and lipid metabolism parameters in drug-naïve, antipsychotic-treated, and antipsychotic discontinuation patients with schizophrenia
por: Wu, Xiaoli, et al.
Publicado: (2014)

Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia
por: Ascher-Svanum, Haya, et al.
Publicado: (2006)

Management of antipsychotic treatment discontinuation and interruptions using model-based simulations
por: Samtani, Mahesh N, et al.
Publicado: (2012)

Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation
por: Matza, Louis S, et al.
Publicado: (2012)

Second-Generation Antipsychotic Discontinuation in First Episode Psychosis: An Updated Review
por: Miller, Brian J., et al.
Publicado: (2011)

Multiple dose pharmacokinetics of inhaled loxapine in subjects on chronic, stable antipsychotic regimens
por: Spyker, Daniel A., et al.
Publicado: (2015)

Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation
por: Correll, Christoph U, et al.
Publicado: (2019)

Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia
por: Caroff, Stanley N., et al.
Publicado: (2018)

Using Functional Analysis as a Framework to Guide Individualized Treatment for Negative Symptoms
por: Lincoln, Tania M., et al.
Publicado: (2017)

Early discontinuation and dose reduction of adjuvant chemotherapy in stage III colon cancer patients
por: Boakye, Daniel, et al.
Publicado: (2021)

Multilevel algorithms for wavefront reduction
por: Hu, Y F, et al.
Publicado: (2000)

Statin discontinuation and new antipsychotic use after an acute hospital stay vary by hospital
por: Coe, Antoinette B., et al.
Publicado: (2020)

Dose-tapering trajectories in patients with remitted psychosis undergoing guided antipsychotic reduction to reach minimum effective dose
por: Liu, Chen-Chung, et al.
Publicado: (2023)

A targeted approach to reducing rates of discontinuation and dose reduction in patients receiving sorafenib or regorafenib
por: Nix, Ryan, et al.
Publicado: (2019)

Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics
por: Mahlich, Jörg, et al.
Publicado: (2020)

High Rate of Discontinuation during Long-Acting Injectable Antipsychotic Treatment in Patients with Psychotic Disorders
por: Auxilia, Anna Maria, et al.
Publicado: (2023)

Taking a machine learning approach to optimize prediction of vaccine hesitancy in high income countries
por: Lincoln, Tania M., et al.
Publicado: (2022)

Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab
por: van der Schoot, Lara S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bttoo1pjie293kokui0bargden